A number of research analysts have weighed in on CLSD shares. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Clearside Biomedical in a research report on Thursday, November 14th. StockNews.com upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Thursday, December 12th.Â
Clearside Biomedical, Inc. (NASDAQ:CLSDÂ –Â Get Free Report) shares crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $0.98 and traded as low as $0.91. Clearside Biomedical shares last traded at $0.94, with a volume of 187,724 shares.
Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price target on shares of Clearside Biomedical in a research report on Wednesday, November 13th.
Finally, Chardan Capital reissued a “buy” rating and issued a $6.00 price objective on shares of Clearside Biomedical in a research report on Friday, November 15th.
One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Clearside Biomedical currently has an average rating of “Moderate Buy” and a consensus price target of $5.33.
The company’s 50 day moving average is $0.97 and its 200-day moving average is $1.07. The stock has a market cap of $85.70 million, a PE ratio of -2.51 and a beta of 2.22.
Clearside Biomedical (NASDAQ:CLSDÂ –Â Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.04.
The business had revenue of $1.04 million during the quarter, compared to analyst estimates of $0.25 million. During the same quarter last year, the firm posted ($0.15) EPS. As a group, analysts forecast that Clearside Biomedical, Inc. will post -0.48 EPS for the current year.
